GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British ...

On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on ...

Belantamab mafodotin is under clinical development by GSK and currently in Phase I for Systemic Lupus Erythematosus.

Also Read: GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market – Here's Why People with CRSwNP experience symptoms such as nasal obstruction, loss of smell ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an increase in overall survival (OS) with the drug had reached statistical ...

GSK's BCMA-directed antibody-drug conjugate Blenrep reduced the risk of death by 42% in a multiple myeloma trial that the company believes could be practice-changing. The DREAMM-7 study showed ...

(Alliance News) - GSK PLC on Friday reported that its Nucala treatment has been approved in China to treat long-term sufferers of a sinus ailment following a phase 3 study. The London-based ...

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience. To access our Live RNS you must confirm you are a private ...